CTLA4 and melanoma: Recent studies have indicated that a high tumor mutation burden increases responsiveness to CTLA-4 inhibition in melanoma, to PD-1 inhibition in non-small cell lung cancer and in mismatch repair-deficient colorectal cancers [147].